Coming to you from Congress, we're taking a look at the Oncology Nursing Certification Corporation's (ONCC's) recognition breakfast for oncology-certified nurses. As attendees enjoyed their breakfast with their colleagues, they also recognized the 2023 Certified Nurse of the Year Award recipients; learned from keynote speaker, humorist, and author Jess Pettitt; and even earned NCPD contact hours.

Coming to you from Congress, get a peek at the ONS Learning Hall, where attendees can connect with oncology nursing colleagues; chat with industry experts, sponsors, and advocacy partners; and even find a space to prioritize their well-being. Watch what's in store for attendees in the Learning Hall through Saturday.

Coming to you from Congress®, we get to know the 2023 ONS President's Award recipient, Heather Ferguson, the founder and executive director of the Lymphedema Advocacy Group. Ferguson had a pivotal role in advocating with ONS for the Lymphedema Treatment Act, which was finally passed into law in December 2022 and improves access to care for patients and survivors.

Coming to you from Congress, it's the event you've been waiting for. Bright and early on Thursday morning, attendees at the 48th annual conference made their way to the doors of the Henry B. Gonzalez Convention Center in San Antonio, TX, for the opening ceremony and keynote address. Watch as oncology nurses from near and far arrive on our red carpet.

Macy is a 57-year-old patient with a history of hormone receptor–positive invasive ductal carcinoma of the right breast, diagnosed in 2017. She achieved complete remission after chemotherapy with anthracycline plus paclitaxel followed by bilateral mastectomy with reconstruction in 2018.

Coming to you from Congress, join us as we speak with Oncology Nursing Foundation President Laura Benson about what attendees can expect at the 48th Annual ONS Congress and how oncology nurses everywhere can support the profession.

For nearly 2,500 years, nonmaleficence, or “do no harm,” has been a fundamental tenet of medical ethics. Yet none of today’s U.S. breast, cervical, colorectal, lung, or prostate cancer screening guidelines report all of the harms associated with screening tests, researchers said in study results published in Annals of Internal Medicine.

Under the U.S. Food and Drug Administration’s (FDA’s) fast-track approval process, nadofaragene firadenovec-vncg (Adstiladrin®) became the first gene therapy approved for the treatment of high-risk non-muscle invasive bladder cancer. Approximately 75% of newly diagnosed bladder cancers are classified as non-muscle invasive. Bacillus Calmette Guérin has been used as first-line therapy for more than 20 years, but eventually 30%–50% of patients stop responding, and nadofaragene firadenovec-vncg offers a new treatment option.

On April 19, 2023, the U.S. Food and Drug Administration approved polatuzumab vedotin-piiq (Polivy®) with rituximab, cyclophosphamide, doxorubicin, and prednisone for adult patients who have previously untreated diffuse large B-cell lymphoma, not otherwise specified, or high-grade B-cell lymphoma and who have an International Prognostic Index score of 2 or greater.